IP Library › Granted Patent US 12,377,048
Granted Patent B2
US 12,377,048 · App. 17/152,342 · Granted Aug 5, 2025

Methods of making neutral liposomes containing biologically active agents

Inventors: Richard K. Fisher (Knoxville, TN); Deidra J. H. Mountain (Knoxville, TN); Oscar H. Grandas (Knoxville, TN)
Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
A61K9/1273A61K9/1277A61P9/00C12N15/113C12N2310/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,048
App. No.
17/152,342
Granted
Aug 5, 2025
Kind
B2
Abstract

Processes for preparing neutral liposomes include adding a hydrophobic solution of liposome lipid bilayer precursors and a nucleic acid condenser to an aqueous composition of a nucleic acid condenser and a biologically active ingredient and then, isolating the liposomes. The liposomes are formed from noncationic lipids and encapsulate the biologically active ingredient as a core composition and entrap some of the biologically active ingredient on the exterior surface of the liposome. The liposomes have the nucleic acid condensers and/or cell penetrating peptides attached to the exterior surface of the lipid bilayer. One or more divalent cations are present in the solution with the liposome and remain in solution once the liposomes form.

Claims (19)

1. A process for preparing liposomes, comprising:

adding a hydrophobic solution to an aqueous composition,

wherein the hydrophobic solution comprises ethanol, neutral lipid bilayer precursors, and a stearylated first nucleic acid condenser, wherein the stearylated first nucleic acid condenser comprises octaarginine (R8) of SEQ ID NO: 6 or SEQ ID NO: 7; and

wherein the aqueous composition comprises a nucleic acid;

wherein liposomes form that have the stearylated first nucleic acid condenser incorporated in a membrane of the liposome and wherein the nucleic acid is encapsulated therein as an aqueous core composition; and

isolating the liposomes, wherein the liposomes are less than 100 nm in diameter with a polydispersity index <0.2.

2. The process according to claim 1 , wherein the nucleic acid is DNA or RNA.

3. The process according to claim 2 , wherein the RNA is siRNA, or saRNA.

4. The process according to claim 1 , wherein the liposome further encapsulates a biologically active ingredient selected from one or more of antipyretics, analgesics, anti-malarials, antibiotics, antiseptics, mood stabilizers, hormones, contraceptives, stimulants, tranquilizers, statins, β-receptor blockers, anti-hypertensives, anticoagulants, bronchodilators, corticosteroids, vaccines, antibodies, immunosuppressants, interferons, and enzymes.

5. The process according to claim 1 , wherein the neutral lipid bilayer precursors are chosen from phospholipids, glycolipids, sterols, and membrane stabilizing agents.

6. The process according to claim 5 , wherein the neutral lipid bilayer precursors include pegylated precursors.

7. The process according to claim 1 , wherein the aqueous composition comprises a second nucleic acid condenser, and wherein the second nucleic acid condenser is a divalent cation.

8. The process according to claim 7 , wherein the divalent cation is selected from the group consisting of calcium (Ca 2+ ), magnesium (Mg 2+ ), barium (Ba 2+ ), ferrous (Fe 2+ ), and combinations thereof.

9. The process according to claim 7 , wherein the divalent cation is Ca 2+ .

10. The process according to claim 7 , wherein the second nucleic acid condenser is present at a concentration of about 5 mM to about 50 mM.

11. The process according to claim 10 , wherein the concentration is about 10 mM to about 40 mM.

12. The process according to claim 10 , wherein the concentration is about 5 mM to about 15 mM.

13. The process according to claim 1 , wherein the diameter is in a range of 50 nm to 65 nm.

14. The process according to claim 13 , wherein the aqueous composition comprises a second nucleic acid condenser, and wherein the second nucleic acid condenser is a divalent cation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2025
From: FISHER, RICHARD K.; MOUNTAIN, DEIDRA J.H.; GRANDAS, OSCAR H.
To: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Reel/Frame 070811/0955 →
Continuity (3)
Continuation PCTUS2019042600 · Jul 19, 2019
Provisional Application 62701759 · Jul 21, 2018
Related Publication 20210244665A1 · Aug 12, 2021
References Cited (50)
US 4241046A · Papahadjopoulos et al. · 1980 [cited by applicant]
KR 20110114952A · 2011 [cited by applicant]
WO 2000003683A2 · 2000 [cited by applicant]
WO 2010110471A1 · 2010 [cited by applicant]
Somiya et al., One-step scalable preparation method for non-cationic liposomes with high siRNA content, May 28, 2015, Internation Journal of Pharmaceutics, 490, 316-323 (Year: 2015). [cited by examiner]
Nakamura et al., Octaarginine-modified multifunctional envelope-type nano device for siRNA, Mar. 23, 2007, Journal of Controlled Release, 119, 360-367. (Year: 2007). [cited by examiner]
Jiang et al., Gene delivery to tumor cells by cationic polymeric nanovectors coupled to folic acid and the cell-penetrating peptide octaarginine, Jun. 28, 2011, Biomaterials, 32, 7253-7262 (Year: 2011). [cited by examiner]
Torchilin et al., Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes, Feb. 18, 2003, Proceedings of the National Academy of Sciences, 100, 1972-1977 (Year: 2003). [cited by examiner]
Khalil, I.A. et al., High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression, 2006, Journal of Biological Chemistry, vol. 281, 3544-3551 (Year: 2006). [cited by examiner]
Bochicchio, S. et al., Liposomes as siRNA delivery vectors, 2014, Current Drug Metabolism, vol. 15, 882-892 (Year: 2014). [cited by examiner]
Pattni et al., New developments in liposomal drug delivery, Chemical Reviews, 2015, 10938-66, 115. [cited by applicant]
Aryasomayajula et al., Multifunctional Liposomes, Cancer Nanotechnology, 2017, 41-61, Springer. [cited by applicant]
Johnson et al., Single bilayer liposomes, Biochimica et Biophysica Acta (BBA)-Biomembranes, 1971, 820-6, 233. [cited by applicant]
Bunker et al., Rational design of liposomal drug delivery systems, a review: combined experimental and computational studies of lipid membranes, liposomes and their PEGylation, Biochimica et Biophysica Acta (BBA)-Biomem… [cited by applicant]
Sercombe et al., Advances and challenges of liposome assisted drug delivery, Frontiers in Pharmacology, 2015, 286, 6. [cited by applicant]
Noble et al., Ligand-targeted liposome design: challenges and fundamental considerations, Trends in Biotechnology, 2014, 32-45, 32. [cited by applicant]
Miller AD, Cationic liposomes for gene therapy, Angewandte Chemie International Edition, 1998, 1768-85, 37. [cited by applicant]
Saul et al., A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers, Journal of Controlled Release, 2006, 277-87, 114. [cited by applicant]
Zylberberg et al., Engineering liposomal nanoparticles for targeted gene therapy, Gene Therapy, 2017, 441, 24. [cited by applicant]
Garg et al., Liposomes: targeted and controlled delivery system, Drug Delivery Letters 2014, 62-71, 4. [cited by applicant]
Wasungu et al., Cationic lipids, lipoplexes and intracellular delivery of genes, Journal of Controlled Release 2006, 255-64, 116. [cited by applicant]
Antipina et al., Molecular mechanism of calcium-induced adsorption of DNA on zwitterionic phospholipid membranes, The Journal of Physical Chemistry, Apr. 20, 2015, 6638-45, 119. [cited by applicant]
Koren et al., Cell-penetrating peptides: breaking through to the other side, Trends in Molecular Medicine, 2012, 385-93, 18. [cited by applicant]
Yang et al., Cell-penetrating peptide induces leaky fusion of liposomes containing late endosome-specific anionic lipid, Biophysical Journal, 2010, 2525-33, 99. [cited by applicant]
Schmidt et al., Arginine-rich cell-penetrating peptides, FEBS Letters, 2010, 1806-13, 584. [cited by applicant]
Somiya et al., One-step scalable preparation method for non-cationic liposomes with high siRNA content, International Journal of Pharmaceutics, 2015, 316-23, 490. [cited by applicant]
Fisher et al., Improving the efficacy of liposome-mediated vascular gene therapy via lipid surface modifications, Journal of Surgical Research, 2017, 136-44, 219. [cited by applicant]
Kim et al., Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid, International Journal of Pharmaceutics, 2010, 141-7, 392. [cited by applicant]
Kogure et al., Development of a non- viral multifunctional envelope-type nano device by a novel lipid film hydration method, Journal of Controlled Release 2004, 317-23, 98. [cited by applicant]
Lee et al., Topology of surface ligands on liposomes: characterization based on the terms, incorporation ratio, surface anchor density, and reaction yield, Biological and Pharmaceutical Bulletin, 2016, 1983-94, 39. [cited by applicant]
Uster et al., Insertion of poly (ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time, FEBS Letters, 1996, 243-6, 386. [cited by applicant]
Sułkowski et al., The influence of temperature, cholesterol content and pH on liposome stability, Journal of Molecular Structure, 2005, 737-47, 744. [cited by applicant]
Iden et al., In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach, Biochimica et Biophysica Acta (BBA)-Biomembranes, 2001, 207-16, … [cited by applicant]
Moreira et al., Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity, Pharmaceutical Research, 2002, 265-9, 19. [cited by applicant]
Nakamura et al., Octaarginine-modified multifunctional envelope-type nano device for siRNA, Journal of Controlled Release, 2007, 360-7, 119. [cited by applicant]
Zhang et al., Cationic lipids and polymers mediated vectors for delivery of siRNA, Journal of Controlled Release, 2007, 1-10, 123. [cited by applicant]
Torchilin VP. Multifunctional nanocarriers, Advanced Drug Delivery Reviews, 2012, 302-15, 64. [cited by applicant]
Gao et al., Cell-penetrating peptide-based intelligent liposomal systems for enhanced drug delivery, Current pharmaceutical biotechnology, 2014, 210-9, 15. [cited by applicant]
Copolovici et al., Cell-penetrating peptides: design, synthesis, and applications, ACS Nano, 2014, 1972-94, 8. [cited by applicant]
Karmali et al., Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises, Medicinal Research Reviews, 2007, 696-722, 27. [cited by applicant]
Safinya et al., Cationic liposome-nucleic acid complexes for gene delivery and gene silencing, New Journal of Chemistry, 2014, 5164-72, 38. [cited by applicant]
Kogure et al., Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system, Advanced Drug Delivery Reviews, 2008, 559-71, 60. [cited by applicant]
33. Soenen et al., Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model, Biomaterials, 2009, 3691-701, 30. [cited by applicant]
Holland et al., Poly (ethylene glycol)—lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine, Biochemistry, 1996, 2618-24, 35. [cited by applicant]
El-Sayed et al., Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment, The AAPS Journal, 2009, 13-22, 11. [cited by applicant]
Chan et al., Endosomal escape and transfection efficiency of PEGylated cationic liposome-DNA complexes prepared with an acid-labile PEG-lipid, Biomaterials, 2012, 4928-35, 33. [cited by applicant]
Mattern-Schain et al., Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics, Chemistry and Physics of Lipids, 2019, 149-57, 218. [cited by applicant]
International Search Report and Written Opinion, PCT/US2019/042600, Nov. 21, 2019 (11 pages). [cited by applicant]
Extended European Search Report , Application No. 19840350.3, Jul. 6, 2022 (147 pages). [cited by applicant]
Bruno, Using drug-excipient interactions for siRNA delivery, Advanced Drug Delivery Reviews, Sep. 14, 2011, p. 1210-1226, vol. 63. [cited by applicant]